INTRODUCTION

High-Risk Skin Cancer

The majority of nonmelanoma skin cancers have excellent prognosis and are effectively treated with local, minimally invasive surgical or destructive techniques. However, the rising incidence of skin cancer combined with lengthened survival of the elderly, immunosuppressed, and at-risk populations has resulted in an increasing number of locally advanced, regional, and distantly metastatic disease. This subset of high-risk cases results in significant morbidity and mortality. As experts in skin cancers, dermatologists are at the forefront of the diagnosis, management, and investigation of novel therapies. Accurate diagnosis, risk stratification, staging, and a multidisciplinary approach are critical for optimizing patient outcome. Thank you to our colleagues in medical, surgical, and radiation oncology for the collaborative care of our most challenging patients. In recent years, the development of targeted molecular therapy and immunotherapy has revolutionized the treatment of locally advanced and metastatic disease. I would like to thank the contributing authors for summarizing the advances in the field and providing us with knowledge regarding the management of high-risk skin cancer patients.

Siegrid S. Yu, MD
Professor of Dermatology
Director, Micrographic Surgery
and Dermatologic Oncology Fellowship
University of California, San Francisco

In recent years, the development of targeted molecular therapy and immunotherapy has revolutionized the treatment of locally advanced and metastatic disease.